Search

Your search keyword '"Zsigmond, Ferenc"' showing total 14 results
Start Over Author "Zsigmond, Ferenc"
14 results on '"Zsigmond, Ferenc"'

1. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis

Author

Stehlk, Jiri, Bonderup, Ole, Munck, Lars Kristian, Rannem, Terje, Armerding, Peter, Bläker, Michael, Böhm, Günter, Hoesl, Mark, Kirsch, Christian, Madisch, Ahmed, Meier, Eberhard, Miehlke, Stephan, Rehbehn, Kai-Uwe, Kiss, Gyula G., Nagy, Ferenc, Tulassay, Zsolt, Zsigmond, Ferenc, Kupcinskas, Limas, Bouma, Gerd, Pierik, Marieke, Fernández-Bañares, Fernando, Lucendo, Alfredo J., Bohr, Johan, Hellström, Per, Lebrun, Barbro, Lindberg, Greger, Münch, Andreas, Vigren, Lina, Wielondek, Miroslav, Krauss, Martin, Dignass, Axel, Kruis, Wolfgang, Aust, Daniela, Mihaly, Emese, Böhm, Günther, Kupcinskas, Juozas, Nacak, Tanju, and Greinwald, Roland

Published
2018
Full Text
View/download PDF

2. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

Author

Bálint, Anita, Farkas, Klaudia, Palatka, Károly, Lakner, Lilla, Miheller, Pál, Rácz, István, Hegede, Gábor, Vincze, Áron, Horváth, Gábor, Szabó, Andrea, Nagy, Ferenc, Szepes, Zoltán, Gábor, Zoltán, Zsigmond, Ferenc, Zsóri, Ágnes, Juhász, Márk, Csontos, Ágnes, Szűcs, Mónika, Bor, Renáta, Milassin, Ágnes, Rutka, Mariann, and Molnár, Tamás

Published
2016
Full Text
View/download PDF

4. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study

Author

Bor, Renáta, primary, Fábián, Anna, additional, Matuz, Mária, additional, Szepes, Zoltán, additional, Farkas, Klaudia, additional, Miheller, Pál, additional, Szamosi, Tamás, additional, Vincze, Áron, additional, Rutka, Mariann, additional, Szántó, Kata, additional, Bálint, Anita, additional, Nagy, Ferenc, additional, Milassin, Ágnes, additional, Tóth, Tibor, additional, Zsigmond, Ferenc, additional, Bajor, Judit, additional, Müllner, Katalin, additional, Lakner, Lilla, additional, Papp, Mária, additional, Salamon, Ágnes, additional, Horváth, Gábor, additional, Sarang, Krisztina, additional, Schäfer, Eszter, additional, Sarlós, Patrícia, additional, Palatka, Károly, additional, and Molnár, Tamás, additional

Published
2019
Full Text
View/download PDF

5. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis

Author

Miehlke, Stephan, primary, Aust, Daniela, additional, Mihaly, Emese, additional, Armerding, Peter, additional, Böhm, Günther, additional, Bonderup, Ole, additional, Fernández-Bañares, Fernando, additional, Kupcinskas, Juozas, additional, Munck, Lars Kristian, additional, Rehbehn, Kai-Uwe, additional, Nacak, Tanju, additional, Greinwald, Roland, additional, Münch, Andreas, additional, Stehlk, Jiri, additional, Rannem, Terje, additional, Bläker, Michael, additional, Böhm, Günter, additional, Hoesl, Mark, additional, Kirsch, Christian, additional, Madisch, Ahmed, additional, Meier, Eberhard, additional, Miehlke, Stephan, additional, Kiss, Gyula G., additional, Nagy, Ferenc, additional, Tulassay, Zsolt, additional, Zsigmond, Ferenc, additional, Kupcinskas, Limas, additional, Bouma, Gerd, additional, Pierik, Marieke, additional, Lucendo, Alfredo J., additional, Bohr, Johan, additional, Hellström, Per, additional, Lebrun, Barbro, additional, Lindberg, Greger, additional, Vigren, Lina, additional, Wielondek, Miroslav, additional, Krauss, Martin, additional, Dignass, Axel, additional, and Kruis, Wolfgang, additional

Published
2018
Full Text
View/download PDF

6. Az adalimumab hatékonysága és biztonságossága hagyományos kezelésre refrakter colitis ulcerosában

Author

Rutka, Mariann, primary, Bálint, Anita, additional, Farkas, Klaudia, additional, Palatka, Károly, additional, Lakner, Lilla, additional, Miheller, Pál, additional, Rácz, István, additional, Hegede, Gábor, additional, Vincze, Áron, additional, Horváth, Gábor, additional, Szabó, Andrea, additional, Nagy, Ferenc, additional, Szepes, Zoltán, additional, Gábor, Zoltán, additional, Zsigmond, Ferenc, additional, Zsóri, Ágnes, additional, Juhász, Márk, additional, Csontos, Ágnes, additional, Szűcs, Mónika, additional, Bor, Renáta, additional, Milassin, Ágnes, additional, and Molnár, Tamás, additional

Published
2016
Full Text
View/download PDF

7. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study

Author

Bor, Renáta, Fábián, Anna, Matuz, Mária, Szepes, Zoltán, Farkas, Klaudia, Miheller, Pál, Szamosi, Tamás, Vincze, Áron, Rutka, Mariann, Szántó, Kata, Bálint, Anita, Nagy, Ferenc, Milassin, Ágnes, Tóth, Tibor, Zsigmond, Ferenc, Bajor, Judit, Müllner, Katalin, Lakner, Lilla, Papp, Mária, Salamon, Ágnes, Horváth, Gábor, Sarang, Krisztina, Schäfer, Eszter, Sarlós, Patrícia, Palatka, Károly, and Molnár, Tamás

Abstract

ABSTRACTBackground: GEMINI trials demonstrated the therapeutic efficacy of vedolizumab (VDZ) in Crohn’s disease (CD) and ulcerative colitis (UC).Research design and methods: Aim of this study was to determine the real-life effectiveness of VDZ on endoscopic healing in the Hungarian nationwide cohort of inflammatory bowel disease (IBD) patients based on the changes on clinical and endoscopic scores. Every adult IBD patient in the country (121 UC and 83 CD) who completed the short-term VDZ therapy was enrolled, of which 72 UC and 52 CD patients could complete the long-term therapy.Results: The rates of endoscopic healing were substantially higher in UC compared with CD patients during the short- and long-term therapy (52.9% vs. 21.7%, p< 0.0001, and 51.4% vs. 21.2%, p= 0.015, respectively). In CD, the rate of endoscopic healing was lower at week 14 compared with week 22 (14.5% vs. 37.0%, p= 0.026). Prior anti-TNF-α therapy (88.73%) was not associated with a significant decrease in therapeutic response. The average disease duration was significantly lower in CD patients achieving endoscopic healing at week 52 (11.75 vs. 5.27 years, p= 0.007).Conclusions: VDZ therapy is an effective therapeutic option in anti-TNF-α refractory IBD. However, the endoscopic healing rate was substantially lower and showed a significant delay in CD compared with UC.

Published
2020
Full Text
View/download PDF

8. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

Author

Bálint, Anita, primary, Farkas, Klaudia, additional, Palatka, Károly, additional, Lakner, Lilla, additional, Miheller, Pál, additional, Rácz, István, additional, Hegede, Gábor, additional, Vincze, Áron, additional, Horváth, Gábor, additional, Szabó, Andrea, additional, Nagy, Ferenc, additional, Szepes, Zoltán, additional, Gábor, Zoltán, additional, Zsigmond, Ferenc, additional, Zsóri, Ágnes, additional, Juhász, Márk, additional, Csontos, Ágnes, additional, Szűcs, Mónika, additional, Bor, Renáta, additional, Milassin, Ágnes, additional, Rutka, Mariann, additional, and Molnár, Tamás, additional

Published
2015
Full Text
View/download PDF

10. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohnʼs disease, while smoking decreases the risk of colectomy in ulcerative colitis

Author

Szamosi, Tamas, primary, Banai, Janos, additional, Lakatos, Laszlo, additional, Czegledi, Zsofia, additional, David, Gyula, additional, Zsigmond, Ferenc, additional, Pandur, Tunde, additional, Erdelyi, Zsuzsanna, additional, Gemela, Orsolya, additional, Papp, Maria, additional, Papp, Janos, additional, and Lakatos, Peter Laszlo, additional

Published
2010
Full Text
View/download PDF

12. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s disease

Author

Lakatos, Peter Laszlo, primary, Czegledi, Zsofia, additional, Szamosi, Tamas, additional, Banai, Janos, additional, David, Gyula, additional, Zsigmond, Ferenc, additional, Pandur, Tunde, additional, Erdelyi, Zsuzsanna, additional, Gemela, Orsolya, additional, Papp, Janos, additional, and Lakatos, Laszlo, additional

Published
2009
Full Text
View/download PDF

13. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].

Author

Rutka M, Bálint A, Farkas K, Palatka K, Lakner L, Miheller P, Rácz I, Hegede G, Vincze Á, Horváth G, Szabó A, Nagy F, Szepes Z, Gábor Z, Zsigmond F, Zsóri Á, Juhász M, Csontos Á, Szűcs M, Bor R, Milassin Á, and Molnár T

Subjects
Adalimumab administration & dosage, Adolescent, Adrenal Cortex Hormones administration & dosage, Adult, Anti-Inflammatory Agents administration & dosage, Azathioprine administration & dosage, Child, Child, Preschool, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hungary, Male, Mesalamine administration & dosage, Middle Aged, Prospective Studies, Remission Induction, Severity of Illness Index, Time Factors, Treatment Outcome, Adalimumab therapeutic use, Anti-Inflammatory Agents therapeutic use, Colitis, Ulcerative drug therapy
Abstract

Introduction: Adalimumab was approved for the treatment of ulcerative colitis refractory to conventional therapy several years later than infliximab in Europe. Due to the relatively low remission rate observed in Ultra trials, data on the efficacy of adalimumab in ulcerative colitis are really helpful in the daily practice., Aim: The aim of this study was to prospectively collect data on induction and maintenance adalimumab therapy in patients with ulcerative colitis treated in Hungarian centres., Method: This prospective study collected data of all patients with ulcerative colitis treated with adalimumab in 10 Hungarian centres. The primary endpoints of the study were rates of remission, response and primary failure at week 12, and the rate of continuous clinical response, remission and loss of response at weeks 30, and 52. Secondary endpoints were endoscopic outcome at week 52 and comparison of the efficacy of adalimumab between treatment naive and infliximab-experienced patients., Results: 73 patients with active ulcerative colitis were enrolled in the study. 75.3% of the patients exhibited clinical response after the induction at week 12. The probability of maintaining adalimumab treatment was 48.6% at week 52 with a continuous clinical response in 92% of these patients. Mucosal healing was achieved in 48.1% of the patients at week 52. Dose intensification was performed in 17.6% of the patients. Minor side effects developed in 4% of the patients and 5.4% of the patients underwent colectomy during the 1-year treatment period., Conclusions: These results coming from the real clinical setting demonstrate a favourable efficacy of adalimumab induction and maintenance therapy in patients with ulcerative colitis.

Published
2016
Full Text
View/download PDF

14. [Self-expanding metal stents for palliation of malignant oesophageal obstruction].

Author

Tolmácsi B, Rábai K, Szamosi T, Czeglédi Z, Gyökeres T, Zsigmond F, and Banai J

Subjects
Adult, Aged, Aged, 80 and over, Carcinoma physiopathology, Deglutition, Deglutition Disorders etiology, Equipment Design, Esophageal Fistula etiology, Esophageal Neoplasms physiopathology, Esophageal Stenosis complications, Esophageal Stenosis physiopathology, Female, Foreign-Body Migration, Humans, Male, Middle Aged, Reoperation, Treatment Outcome, Carcinoma complications, Esophageal Neoplasms complications, Esophageal Stenosis etiology, Esophageal Stenosis surgery, Palliative Care methods, Stents
Abstract

Background: Malignant oesophageal stenosis can be caused by cancer of the oesophagus, gastric cardia, lungs, mediastinum or, rarely, breast. Most of these cases are inoperable due to advanced stage of the disease, comorbidities or age of the patients; and palliative treatment can be applied only. The quality of life is mostly determined by the extent of dysphagia. Several methods are available to palliate dysphagia. Hereby, the authors review their results with palliation of malignant oesophageal obstruction applying self-expanding metal stents., Patients and Methods: 68 endoscopic stent implantations were performed in 64 patients (15 female and 49 male) with malignant dysphagia between 2003 and 2008. After radiological investigations, distally deployed covered stents with or without an antireflux valve were placed, depending on the localization of the tumour. In one patient with a stenosis localized in the upper third of the oesophagus a proximally deployed covered stent was used. The aim was to re-establish oral nutrition and cover possible fistulas., Results: Significant improvement of swallowing was detected in every patient. Average dysphagia score has improved from 3.2 to 1.7. Technical difficulties during stenting occurred in a relatively low percentage of patients only (2 in 68; i.e. 2.94%). Fistulas were covered in every case. Early stent migration (<7 days) happened in one case. One patient suffered non-fatal myocardial infarction two days after stent placement. In 5 cases tumour in- and overgrowth, in 4 cases bleeding was seen as late complications. Oesophago-tracheal fistula was noted in three patients after stent implantation. Late stent migration (>7 days) occurred in two patients. Re-stenting was necessary in four cases, while three patients needed an upper GI endoscopy for cleansing the stent caused by food obstruction., Conclusions: According to our data self-expanding metal stents are highly effective and safe for improving dysphagia. Stent-related complications are relatively rare. This method is highly recommended for palliation of malignant dysphagia.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results